Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Hyundai Pharmaceutical Co Company

004310.KS
KR7004310009

Price

3,870.00
Today +/-
-0.01
Today %
-0.52 %
P

Hyundai Pharmaceutical Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Hyundai Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Hyundai Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Hyundai Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Hyundai Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Hyundai Pharmaceutical Co Stock Price History

DateHyundai Pharmaceutical Co Price
10/30/20243,870.00 undefined
10/29/20243,890.00 undefined
10/28/20243,900.00 undefined
10/25/20243,860.00 undefined
10/24/20243,885.00 undefined
10/23/20244,050.00 undefined
10/22/20244,145.00 undefined
10/21/20244,240.00 undefined
10/18/20244,335.00 undefined
10/17/20244,330.00 undefined
10/16/20244,150.00 undefined
10/15/20244,145.00 undefined
10/14/20244,170.00 undefined
10/11/20244,225.00 undefined
10/10/20244,485.00 undefined
10/8/20244,345.00 undefined
10/7/20244,400.00 undefined
10/4/20244,415.00 undefined
10/2/20244,265.00 undefined

Hyundai Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hyundai Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hyundai Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hyundai Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hyundai Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hyundai Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hyundai Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hyundai Pharmaceutical Co’s growth potential.

Hyundai Pharmaceutical Co Revenue, EBIT and net profit per share

DateHyundai Pharmaceutical Co RevenueHyundai Pharmaceutical Co EBITHyundai Pharmaceutical Co Net Income
2023180.76 B undefined6.93 B undefined6.12 B undefined
2022162.69 B undefined7.97 B undefined-164.58 M undefined
2021139.8 B undefined-1.57 B undefined-3.17 B undefined
2020132.97 B undefined3.05 B undefined2.19 B undefined
2019134.65 B undefined2.04 B undefined1.21 B undefined
2018130.79 B undefined-2.66 B undefined-2.11 B undefined
2017130.48 B undefined2.01 B undefined1.46 B undefined
2016120.02 B undefined2.47 B undefined1.4 B undefined
2015109.83 B undefined1.71 B undefined1.59 B undefined
2014107.84 B undefined2.25 B undefined1.47 B undefined
2013108.14 B undefined2.19 B undefined1.42 B undefined
2012102.25 B undefined-4.32 B undefined-4.85 B undefined
2011114.28 B undefined3.46 B undefined520 M undefined
2010111.86 B undefined1.09 B undefined2.97 B undefined
2009122.88 B undefined2.96 B undefined1.67 B undefined
2008120.52 B undefined4.24 B undefined3.48 B undefined
2007111.66 B undefined6.8 B undefined9.74 B undefined
2006103.52 B undefined9.83 B undefined6.61 B undefined
2005101.16 B undefined8.88 B undefined6.17 B undefined
2004106.82 B undefined6.81 B undefined5.26 B undefined

Hyundai Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
87.2167.7773.5678.7598.52110.38106.24106.82101.16103.52111.66120.52122.88111.86114.28102.25108.14107.84109.83120.02130.48130.79134.65132.97139.8162.69180.76
--22.298.557.0525.1112.03-3.750.54-5.302.337.877.931.96-8.972.16-10.525.75-0.281.859.288.710.242.95-1.255.1416.3711.11
44.1340.0243.6142.1746.0745.9544.6043.2846.0450.2449.5544.3141.7342.7740.1838.4037.6538.5138.4948.6647.5046.2347.3043.8640.2842.3142.37
38.4927.1232.0833.2145.3950.7247.3846.2346.5752.0155.3353.451.2847.8445.9139.2740.7141.5342.2858.461.9860.4763.6858.3256.3168.8476.59
8.855.975.917.139.038.116.016.818.889.836.84.242.961.093.46-4.322.192.251.712.472.01-2.662.043.05-1.577.976.93
10.148.818.039.059.167.355.656.378.789.496.093.522.410.973.03-4.222.022.091.552.051.54-2.031.522.30-1.124.903.83
3.211.51.875.067.748.024.755.266.176.619.743.481.672.970.52-4.851.421.471.591.41.46-2.111.212.19-3.17-0.166.12
--53.3024.72170.3053.003.55-40.7810.7417.337.2147.20-64.31-51.9177.62-82.48-1,032.69-129.183.758.58-12.364.37-244.44-157.6080.30-245.08-94.83-3,832.32
---------------------------
---------------------------
13162427272626262525282725252424242424252428272727.8827.8127.11
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Hyundai Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hyundai Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                     
4.095.8710.9313.217.6815.8719.0219.8120.7822.7526.0413.197.6511.3213.9716.6114.6313.7910.418.628.237.367.519.8821.9233.7818.29
43.6837.8732.627.7727.4532.7532.3133.6435.6936.9537.6444.7853.250.9454.0743.1442.6143.7847.2851.0356.5841.0141.5639.4336.8737.3738.38
1.620.070.060.030.030.030.070.070.490.680.841.621.881.461.92.182.162.2203.243.022.823.542.933.475.090.6
6.824.566.518.7513.4912.6310.9412.0813.6217.117.0914.1316.0214.0317.0624.120.9719.3618.5617.1217.2117.4517.9317.3422.0224.0827
0.450.50.310.250.440.480.360.080.10.580.332.580.340.560.510.140.110.120.120.11.890.751.120.920.621.331.21
56.6548.8750.45059.0961.7662.765.6970.6978.0681.9476.2979.0878.3287.5186.1780.4879.2776.3780.186.9369.3971.6580.584.9101.6485.47
10.429.8810.149.4526.5727.8827.5726.7726.4828.3835.4347.7446.3243.1740.7333.133.3532.7132.4532.663332.0230.5929.5729.2628.629.44
6.425.225.385.815.145.194.584.714.376.175.134.947.017.3824.3325.8326.0231.9834.4230.5729.4730.7430.4628.8129.3129.7930.55
000000000000000000000004847.7200
0.450.570.480.130.10.090.30.290.590.620.620.690.50.382.452.411.831.791.753.23.87.537.712.5413.4717.35.63
000000000000000000000000000
2.012.332.021.291.090.81.431.380.91.131.081.051.351.751.942.391.731.551.551.691.426.426.856.036.873.823.53
19.31818.0216.6732.933.9633.8833.1532.3436.342.2654.4155.1952.6769.4463.7362.9368.0370.1768.1367.6976.7275.67778.9679.5269.16
75.9566.8768.4266.6791.9995.7196.5798.84103.02114.36124.2130.7134.27130.98156.95149.9143.4147.3146.54148.23154.62146.11147.24157.5163.86181.16154.63
                                                     
6.189.0113.1213.511414141414141414141414141414141414161616161616
2.142.353.82.662.842.823.043.33.957.016.686.686.396.396.396.396.396.397.097.617.6115.7235.3820.4720.4720.6520.65
21.4222.4524.0428.3534.4340.6744.3748.152.6657.5565.2266.5966.6668.4180.2374.4275.3674.875.6472.472.4752.8351.9752.2948.3549.652.95
0.130.290.39-1.15-2.84-2.79-2.75-3.68-4.38-1.110-11.88-11.47-13.53-13.53-12.65000002.41-18.32000-20.4
-1-1.1-0.950.3917.4517.2116.6716.7517.1417.4717.4717.2417.0217.2516.7717.0718.4923.0418.7716.5519.1717.77-0.8516.4516.8416.915.46
28.863340.3943.7565.8871.975.3378.4783.3894.92103.3792.6392.692.51103.8699.23114.24118.22115.5110.56113.25104.7384.18105.21101.67103.1584.66
7.974.876.14.675.784.974.944.673.62.913.224.165.133.165.085.566.868.497.279.9111.0212.9511.5412.6916.5518.0711.83
1.841.141.281.712.751.861.311.61.021.251.411.561.711.250.560.550.40.50.560.880.941.3701.852.633.112.68
6.175.326.4912.0914.0311.1998.59.569.6911.578.597.829.0611.68.428.648.198.656.87.614.1816.8812.8212.1530.1612.2
000000000000000000026.9429.45212124142938
14.1810.88.1800.180.270.7300.05001923.522227.8229.2920.7518.762100000.420.520.350.62
30.1622.1222.0418.4722.7418.2815.9914.7714.2313.8516.233.3238.1935.4745.0643.8236.6435.9437.4944.5249.0249.5149.4251.7845.8580.765.33
11.356.311.191.190.730000000000000000000.2115.3210.090.58
000000000.081.341.841.060.590.883.62.131.932.531.490.30.45000000
5.585.444.83.272.645.535.265.65.344.262.793.692.92.123.984.273.624.143.135.657.058.4813.6415.3816.083.824.05
16.9311.755.994.463.375.535.265.65.425.64.634.753.4937.586.45.556.674.625.947.58.4813.6415.5831.4113.914.63
47.0933.8728.0322.9326.1123.8121.2420.3719.6519.4520.8338.0741.6738.4852.6350.2242.1942.6142.1150.4756.5257.9863.0667.3677.2694.669.97
75.9566.8768.4266.6791.9995.7196.5798.84103.02114.36124.2130.7134.27130.98156.49149.44156.43160.83157.61161.02169.77162.71147.24172.57178.93197.76154.63
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hyundai Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hyundai Pharmaceutical Co's financial health and stability.

Assets

Hyundai Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hyundai Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hyundai Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hyundai Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
3.211.51.875.067.748.024.755.266.176.619.743.481.672.970.54-4.851.461.471.591.41.46-2.111.212.19-3.17-0.166.12
1.060.91.291.232.552.162.161.931.952.082.32.632.612.292.472.362.111.911.972.242.533.23.514.113.983.33.3
0038-816345414-13461967637807-641-339-920000000000000
-9.62.483.114.51-3.07-9.34-1.78-4.6-7.46-8.5-4.84-11.71-14.76-2.12-2.21-3.471.61-3.18-8.45-10.34-9.160.12-4.221.56-1.04-1.02-31.54
2.382.372.374.392.230.823.752.762.673.32-1.815.153.94-0.375.463.262.782.812.053.963.192.195.212.945.369.5117.57
000000000000001.361.280.970.70.590.640.920.730.680.60.711.021.93
000000000000001.11.230.410.353.021.150.340.690.690.78-0.072.192.29
-2.957.258.6814.379.82.088.745.414.294.146.2-1.1-6.892.686.27-2.77.953.01-2.85-2.75-1.983.45.7110.85.1311.62-4.55
-1,168-704-1,707-647-2,040-6,272-2,342-1,530-2,089-3,734-14,310-17,610-2,372-4,623-4,017-2,110-2,264-1,248-2,485-3,680-3,103-3,231-2,359-6,401-6,808-6,583-6,104
-2.38-0.04-0.4-4.82-4.07-7.895.39-1.96-4.03-5.79-8.03-4.49-3.265.92-2.934.81-0.71-0.33-5.08-2.762.58-6.04-2.73-12.39-0.03-9.99-3.09
-1.210.661.3-4.17-2.03-1.627.73-0.43-1.94-2.056.2813.13-0.8910.541.096.921.550.92-2.60.935.68-2.81-0.37-5.996.78-3.413.02
000000000000000000000000000
5.7-8.6-7.86-8.2-0.28-0.91-0.42-0.9400016.595.21-1.52-0.321.47-8.54-1.992.245.942.52-8.4502.424.449.37-1.8
02.915.28-1-1.200-0.7906.091.63-11.88-0.01-2.0600003.37-1.06-2.3611.4-1.716.250-1.53-3.8
5.01-5.86-2.81-9.45-1.73-2.57-2.19-3.26-1.612.41-0.442.614.81-4.8-1.370.53-9.42-2.984.553.71-0.991.77-2.947.453.257.01-6.43
-0.02-0.04-0.05000000-1.95001.200000000000000
-679-123-180-257-255-1,655-1,778-1,527-1,605-1,727-2,068-2,103-1,599-1,224-1,056-939-882-997-1,056-1,158-1,146-1,180-1,232-1,215-1,184-836-826
-0.331.355.460.14-8.3811.940.19-1.350.77-2.26-2.98-5.343.791.972.64-2.18-0.3-3.38-1.79-0.39-0.870.045.878.368.64-14.06
-4,1226,5466,97313,7267,759-4,1946,4003,8812,202409-8,108-18,709-9,261-1,9452,251-4,8075,6871,766-5,333-6,427-5,0841693,3554,403-1,676.665,039.83-10,649.72
000000000000000000000000000

Hyundai Pharmaceutical Co stock margins

The Hyundai Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hyundai Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hyundai Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hyundai Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Hyundai Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hyundai Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hyundai Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hyundai Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hyundai Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hyundai Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hyundai Pharmaceutical Co Margin History

Hyundai Pharmaceutical Co Gross marginHyundai Pharmaceutical Co Profit marginHyundai Pharmaceutical Co EBIT marginHyundai Pharmaceutical Co Profit margin
202342.37 %3.83 %3.39 %
202242.31 %4.9 %-0.1 %
202140.28 %-1.12 %-2.27 %
202043.86 %2.3 %1.64 %
201947.3 %1.52 %0.9 %
201846.23 %-2.03 %-1.61 %
201747.5 %1.54 %1.12 %
201648.66 %2.05 %1.16 %
201538.49 %1.55 %1.45 %
201438.51 %2.09 %1.36 %
201337.65 %2.02 %1.31 %
201238.4 %-4.22 %-4.74 %
201140.18 %3.03 %0.46 %
201042.77 %0.97 %2.65 %
200941.73 %2.41 %1.36 %
200844.31 %3.52 %2.88 %
200749.55 %6.09 %8.72 %
200650.24 %9.49 %6.39 %
200546.04 %8.78 %6.1 %
200443.28 %6.37 %4.92 %

Hyundai Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Hyundai Pharmaceutical Co earnings per share therefore indicates how much revenue Hyundai Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hyundai Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hyundai Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hyundai Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hyundai Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hyundai Pharmaceutical Co Revenue, EBIT and net profit per share

DateHyundai Pharmaceutical Co Sales per ShareHyundai Pharmaceutical Co EBIT per shareHyundai Pharmaceutical Co Earnings per Share
20236,667.83 undefined255.51 undefined225.81 undefined
20225,849.54 undefined286.56 undefined-5.92 undefined
20215,014.74 undefined-56.38 undefined-113.82 undefined
20204,924.67 undefined113.07 undefined81 undefined
20194,987.04 undefined75.67 undefined44.93 undefined
20184,671.11 undefined-94.89 undefined-75.21 undefined
20175,436.67 undefined83.79 undefined60.75 undefined
20164,800.88 undefined98.64 undefined55.88 undefined
20154,576.21 undefined71.08 undefined66.42 undefined
20144,493.21 undefined93.88 undefined61.17 undefined
20134,505.63 undefined91.13 undefined58.96 undefined
20124,260.54 undefined-179.96 undefined-202.08 undefined
20114,761.5 undefined144.17 undefined21.67 undefined
20104,474.4 undefined43.56 undefined118.72 undefined
20094,915.16 undefined118.24 undefined66.84 undefined
20084,463.7 undefined157.07 undefined128.7 undefined
20073,987.96 undefined242.96 undefined347.71 undefined
20064,140.72 undefined393.08 undefined264.56 undefined
20054,046.36 undefined355.32 undefined246.76 undefined
20044,108.5 undefined261.88 undefined202.23 undefined

Hyundai Pharmaceutical Co business model

Hyundai Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Hyundai Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Hyundai Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio

Hyundai Pharmaceutical Co shares outstanding

The number of shares was Hyundai Pharmaceutical Co in 2023 — This indicates how many shares 27.11 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hyundai Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hyundai Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hyundai Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hyundai Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hyundai Pharmaceutical Co stock splits

In Hyundai Pharmaceutical Co's history, there have been no stock splits.

Hyundai Pharmaceutical Co dividend history and estimates

In 2023, Hyundai Pharmaceutical Co paid a dividend amounting to 0 KRW. Dividend means that Hyundai Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Hyundai Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Hyundai Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Hyundai Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Hyundai Pharmaceutical Co Dividend History

DateHyundai Pharmaceutical Co Dividend
202230 undefined
202130 undefined
202042.5 undefined
201945 undefined
201845 undefined
201750 undefined
201646.21 undefined
201546.21 undefined
201443.77 undefined
201341.34 undefined
201236.48 undefined
201138.91 undefined
201043.77 undefined
200948.64 undefined
200863.23 undefined
200775 undefined
200675 undefined
200570 undefined
200465 undefined

Hyundai Pharmaceutical Co dividend payout ratio

In 2023, Hyundai Pharmaceutical Co had a payout ratio of 78.32%. The payout ratio indicates the percentage of the company's profits that Hyundai Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Hyundai Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Hyundai Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Hyundai Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Hyundai Pharmaceutical Co Payout Ratio History

DateHyundai Pharmaceutical Co Payout ratio
202378.32 %
2022-506.96 %
2021-26.36 %
202052.47 %
2019100.18 %
2018-59.83 %
201782.3 %
201682.69 %
201569.58 %
201471.57 %
201370.13 %
2012-18.05 %
2011179.64 %
201036.87 %
200972.77 %
200849.13 %
200721.57 %
200628.35 %
200528.37 %
200432.14 %
Unfortunately, there are currently no price targets and forecasts available for Hyundai Pharmaceutical Co.

Hyundai Pharmaceutical Co shareholders

%
Name
Stocks
Change
Date
21.88688 % Lee (Han Gu)5,720,29008/31/2023
5.17152 % Lee (Sang Jun)1,351,61208/31/2023
0.88948 % Bio Innotis Co., Ltd.232,47108/31/2023
0.74743 % Dimensional Fund Advisors, L.P.195,3474,1272/29/2024
0.54605 % Art M Plus Co., Ltd.142,71508/31/2023
0.48456 % Kim (Jeong Bae)126,64208/31/2023
0.40558 % Christellar Co Ltd106,00008/31/2023
0.23340 % A & Pep Inc.61,00008/31/2023
0.15959 % Hyundai Pharnaceutical Co., Ltd Employees41,71008/31/2023
0.08192 % Hyundai Natural Co., Ltd.21,41008/31/2023
1
2

Hyundai Pharmaceutical Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Mithra Pharmaceuticals Stock
Mithra Pharmaceuticals
SupplierCustomer0,470,870,350,380,570,61
Acerus Pharmaceuticals Stock
Acerus Pharmaceuticals
SupplierCustomer0,410,630,77-0,250,43-
DAE HWA PHARM Stock
DAE HWA PHARM
SupplierCustomer-0,050,680,700,590,890,61
1

Most common questions regarding Hyundai Pharmaceutical Co

What is the P/E ratio of Hyundai Pharmaceutical Co 2024?

The P/E ratio cannot be calculated for Hyundai Pharmaceutical Co at the moment.

What is the P/S ratio of Hyundai Pharmaceutical Co 2024?

The P/S cannot be calculated for Hyundai Pharmaceutical Co currently.

What is the Quality Investing of Hyundai Pharmaceutical Co?

The Quality Investing for Hyundai Pharmaceutical Co is 6/10.

What is the revenue of Hyundai Pharmaceutical Co 2024?

The revenue cannot currently be calculated for Hyundai Pharmaceutical Co.

How high is the profit of Hyundai Pharmaceutical Co 2024?

The profit cannot currently be calculated for Hyundai Pharmaceutical Co.

What is the business model of Hyundai Pharmaceutical Co

No history available for Hyundai Pharmaceutical Co.

What is the Hyundai Pharmaceutical Co dividend?

Hyundai Pharmaceutical Co pays a dividend of 30 KRW distributed over payouts per year.

How often does Hyundai Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Hyundai Pharmaceutical Co or the company does not pay out a dividend.

What is the Hyundai Pharmaceutical Co ISIN?

The ISIN of Hyundai Pharmaceutical Co is KR7004310009.

What is the Hyundai Pharmaceutical Co ticker?

The ticker of Hyundai Pharmaceutical Co is 004310.KS.

How much dividend does Hyundai Pharmaceutical Co pay?

Over the past 12 months, Hyundai Pharmaceutical Co paid a dividend of 30 KRW . This corresponds to a dividend yield of about 0.78 %. For the coming 12 months, Hyundai Pharmaceutical Co is expected to pay a dividend of 30 KRW.

What is the dividend yield of Hyundai Pharmaceutical Co?

The current dividend yield of Hyundai Pharmaceutical Co is 0.78 %.

When does Hyundai Pharmaceutical Co pay dividends?

Hyundai Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of December, December, December, April.

How secure is the dividend of Hyundai Pharmaceutical Co?

Hyundai Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Hyundai Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 30 KRW are expected. This corresponds to a dividend yield of 0.78 %.

In which sector is Hyundai Pharmaceutical Co located?

Hyundai Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hyundai Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hyundai Pharmaceutical Co from 5/1/2024 amounting to 35 KRW, you needed to have the stock in your portfolio before the ex-date on 3/5/2024.

When did Hyundai Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of Hyundai Pharmaceutical Co in the year 2023?

In the year 2023, Hyundai Pharmaceutical Co distributed 30 KRW as dividends.

In which currency does Hyundai Pharmaceutical Co pay out the dividend?

The dividends of Hyundai Pharmaceutical Co are distributed in KRW.

All fundamentals about Hyundai Pharmaceutical Co

Our stock analysis for Hyundai Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hyundai Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.